ARTICLES BY LOUIS

• Bristol Myers Squibb Buys Mirati: Signal Or Symptom?

  10/10/2023

  This discussion goes well beyond the recent Bristol Myers Squibb deal for Mirati Therapeutics, to thoughts on how we limit patent durations to provide for a robust generics market. Do we actually lower drug prices? 

• More Gene Therapy Outsourcing – Can It Be Quantified?

  10/9/2023

  According to ISR Reports inaugural Gene Therapy CDMO Benchmarking survey, well over half the respondents confirmed a complete manufacturing reliance on external partners. Outsourcing has sure come a long way ... more details within.

• CM² + AI = Better Manufacturing At Your CDMOs

  10/3/2023

  This is the final in our series pursuing the practical use of artificial intelligence (AI) in the biopharma supply chain, guided by Professor Tinglong Dai of Johns Hopkins. A look at continuous processing and monitoring, and AI.

• Big Pharma Advises Biotech On Outsourcing

  9/25/2023

  They say biotech taught pharma how to outsource. So what’s someone who has spent 31 years working in Big Pharma know about outsourcing from the vantage point of smaller organizations? A lot, it turns out.

• AI Beats Back Bad Batches

  9/21/2023

  “I look from a supply-chain perspective,” says AI / supply-chain expert Tingling Dai, “discovery, development, manufacture ... until we put them into clinical use.” And that involves, he says, “keeping track of multiple stakeholders.”

• AI, The Ghost In The Outsourcing Machine

  9/18/2023

  It’s time to get real about artificial intelligence applied specifically to drug development and manufacturing outsourcing; practical supply-chain enhancements to implement right now. Thoughts from an AI supply-chain expert. Part 1.

• In Year 20, “Biopharmaceutical” Remains The Same

  9/15/2023

  Each year, I present some takeaways to Outsourced Pharma readers from BioPlan's important annual survey on bioprocessing. This year, I notice our noisy nomenclature, and present a chart that indicates CDMOs will keep on keeping on.

• Tales Of Outsourcing Woe (Are Good For You)

  9/11/2023

  A global drug development and manufacturing stalwart recently relayed heady outsourcing advice, and tales of what you might call economic woe that provide words of caution to all readers ...

• The Most Difficult Outsourcing Tasks

  9/6/2023

  Hint: According to long-termed Pfizer supply-chain professional Francis Dumont, it is sterile-fill. Learn about that and much more on working effectively with CDMOs to optimize production.

• Ex-Pfizer Pro Tired Of The Word “Strategic”

  8/28/2023

  A few months past the culmination of a 31-year career at Pfizer, Francis Dumont has this seminal thought on drug development and manufacturing outsourcing:  “I’m tired of the word ‘strategic.’”